Compound
← Compound
Official website →
AMGNAmgen INC
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- AMGN
- Moeda das demonstrações
- USD
- Último período anual nesta tabela
- 2025-12-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory condi…
IndustryDrug Manufacturers - General
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
23.78×
P/B
Price divided by book value
17.82×
EV/EBITDA
Enterprise value divided by operating cash generation
15.23×
EV/Revenue
Enterprise value divided by revenue
6.6×
What the company earns
ROE
Return on shareholders’ equity
89.3%
ROA
Return on all assets
9.1%
Gross margin
What remains after product costs
72.7%
Operating margin
What remains after operating the business
33.2%
Net margin
How much of each revenue unit becomes profit
22.9%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
4.9
Total debt
Sum of borrowings
$57.3B
Cash
Cash available to cover it
$13.99B
Current ratio
Short-term assets divided by short-term liabilities
1.37
Free cash flow
Cash left after investing
$3.49B
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.43
Revenue growth
Compared with the same period a year earlier
9.7%
Earnings growth
Compared with the same period a year earlier
65.9%
Dividend yield
Trailing 12-month distributions divided by price
2.6%
Market data provider figures for the latest published period. Informational, not investment advice.
Financial statements(USD)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 26.32B | 28.19B | 33.42B | 36.75B |
| Custo dos produtos | -6.41B | -8.45B | -12.86B | -12.04B |
| Despesas com vendas e administrativas | -5.41B | -6.18B | -7.1B | -7.05B |
| Pesquisa e desenvolvimento | -4.43B |
News about AMGN
The Street · 11 hours ago
Morgan Stanley flags Amgen's edge after heart-drug rival stumbles
Yahoo Finance · 2 days ago
Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
The article presents Merck as having a less diversified current income base than Amgen: Keytruda remains a major contributor, while the company is relying on more than 20 new products and a stated $70 billion commercial opportunity to offset eventual loss of exclusivity. Its dividend increased from $0.81 to $0.85 per share from 2025 to 2026, described as a smaller step-up than Amgen's. The comparison therefore frames Merck's dividend durability as dependent on pipeline execution, while Amgen is selected for its broader product base and faster dividend increases.
Yahoo Finance · 4 days ago
A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too
The failed trial raises the evidence standard for Lilly: reducing Lp(a) will not be enough unless lepodisiran also shows fewer heart attacks and strokes. The article presents Lilly as having more protection than Amgen because the program represents a smaller part of Lilly's overall valuation and the company has a stronger growth engine elsewhere. A disappointing trial could reduce peak-sales expectations, while a successful outcome could strengthen the pipeline.
Follow AMGN and get agent analysis of what is moving the stock.
Open Compound